Fimasartan

DB09279

small molecule investigational

Deskripsi

Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials. Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the brand name Kanarb by Boryung Pharmaceuticals.

Struktur Molekul 2D

Berat 501.65
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half life of elimination is 7-10 h [A20319].
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Tmax is 0.5-1.3 h A20319.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Most is eliminated unchangd in bile with less than 3% in the urine A20319.

Interaksi Obat

699 Data
Duloxetine The risk or severity of orthostatic hypotension and syncope can be increased when Fimasartan is combined with Duloxetine.
Levodopa The risk or severity of hypotension and orthostatic hypotension can be increased when Fimasartan is combined with Levodopa.
Risperidone Fimasartan may increase the hypotensive activities of Risperidone.
Aliskiren The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Fimasartan.
Canagliflozin The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Fimasartan.
Drospirenone The risk or severity of hyperkalemia can be increased when Fimasartan is combined with Drospirenone.
Eplerenone The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Fimasartan.
Semuloparin The risk or severity of hyperkalemia can be increased when Semuloparin is combined with Fimasartan.
Methyclothiazide Methyclothiazide may increase the hypotensive and Electrolyte Disturbance activities of Fimasartan.
Bendroflumethiazide Bendroflumethiazide may increase the hypotensive and Electrolyte Disturbance activities of Fimasartan.
Benzthiazide Benzthiazide may increase the hypotensive and Electrolyte Disturbance activities of Fimasartan.
Cyclothiazide Cyclothiazide may increase the hypotensive and Electrolyte Disturbance activities of Fimasartan.
Hydroflumethiazide Hydroflumethiazide may increase the hypotensive and Electrolyte Disturbance activities of Fimasartan.
Chlorothiazide Chlorothiazide may increase the hypotensive and Electrolyte Disturbance activities of Fimasartan.
Trichlormethiazide Trichlormethiazide may increase the hypotensive and Electrolyte Disturbance activities of Fimasartan.
Polythiazide Polythiazide may increase the hypotensive and Electrolyte Disturbance activities of Fimasartan.
Mebutizide Mebutizide may increase the hypotensive and Electrolyte Disturbance activities of Fimasartan.
Cyclopenthiazide Cyclopenthiazide may increase the hypotensive and Electrolyte Disturbance activities of Fimasartan.
Buthiazide Buthiazide may increase the hypotensive and Electrolyte Disturbance activities of Fimasartan.
Lithium citrate The serum concentration of Lithium citrate can be increased when it is combined with Fimasartan.
Lithium carbonate The serum concentration of Lithium carbonate can be increased when it is combined with Fimasartan.
Lithium hydroxide The serum concentration of Lithium hydroxide can be increased when it is combined with Fimasartan.
Tolvaptan The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Fimasartan.
Trimethoprim The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Fimasartan.
Aripiprazole Aripiprazole may increase the hypotensive activities of Fimasartan.
Aripiprazole lauroxil Aripiprazole lauroxil may increase the hypotensive activities of Fimasartan.
Ciprofloxacin The risk or severity of hyperkalemia can be increased when Fimasartan is combined with Ciprofloxacin.
Cyclosporine The risk or severity of hyperkalemia can be increased when Fimasartan is combined with Cyclosporine.
Nicorandil The risk or severity of hyperkalemia can be increased when Nicorandil is combined with Fimasartan.
Icosapent The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Icosapent.
Mesalazine The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Fimasartan.
Indomethacin The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Indomethacin.
Nabumetone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Nabumetone.
Tenoxicam The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Tenoxicam.
Celecoxib The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Celecoxib.
Tolmetin The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Tolmetin.
Rofecoxib The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Rofecoxib.
Piroxicam The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Piroxicam.
Fenoprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Fenoprofen.
Valdecoxib The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Valdecoxib.
Diclofenac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Diclofenac.
Sulindac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Sulindac.
Flurbiprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Flurbiprofen.
Etodolac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Etodolac.
Mefenamic acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Mefenamic acid.
Naproxen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Naproxen.
Sulfasalazine The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Sulfasalazine.
Phenylbutazone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Phenylbutazone.
Meloxicam The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Meloxicam.
Carprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Carprofen.
Diflunisal The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Diflunisal.
Salicylic acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Salicylic acid.
Meclofenamic acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Meclofenamic acid.
Acetylsalicylic acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Acetylsalicylic acid.
Oxaprozin The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Oxaprozin.
Ketoprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Ketoprofen.
Balsalazide The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Balsalazide.
Ibuprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Ibuprofen.
Lumiracoxib The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Lumiracoxib.
Magnesium salicylate The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Magnesium salicylate.
Salsalate The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Salsalate.
Choline magnesium trisalicylate The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Choline magnesium trisalicylate.
Antrafenine The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Antrafenine.
Aminophenazone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Aminophenazone.
Antipyrine The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Antipyrine.
Tiaprofenic acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Tiaprofenic acid.
Etoricoxib The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Etoricoxib.
Taxifolin The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Taxifolin.
Oxyphenbutazone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Oxyphenbutazone.
Licofelone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Licofelone.
Nimesulide The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Nimesulide.
Benoxaprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Benoxaprofen.
Metamizole The risk or severity of hyperkalemia can be increased when Metamizole is combined with Fimasartan.
Zomepirac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Zomepirac.
Cimicoxib The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Cimicoxib.
Lornoxicam The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Lornoxicam.
Aceclofenac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Aceclofenac.
Zaltoprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Zaltoprofen.
Azapropazone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Azapropazone.
Parecoxib The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Parecoxib.
Salicylamide The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Salicylamide.
Kebuzone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Kebuzone.
Isoxicam The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Isoxicam.
Indoprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Indoprofen.
Ibuproxam The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Ibuproxam.
Floctafenine The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Floctafenine.
Fenbufen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Fenbufen.
Etofenamate The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Etofenamate.
Epirizole The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Epirizole.
Benzydamine The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Benzydamine.
Dexibuprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Dexibuprofen.
Dexketoprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Dexketoprofen.
Droxicam The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Droxicam.
Tolfenamic acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Tolfenamic acid.
Firocoxib The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Firocoxib.
Clonixin The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Clonixin.
Morniflumate The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Morniflumate.
Propacetamol The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Propacetamol.
Talniflumate The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Talniflumate.
Robenacoxib The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Robenacoxib.

Target Protein

Type-1 angiotensin II receptor AGTR1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 22864732
    Kim JH, Lee JH, Paik SH, Kim JH, Chi YH: Fimasartan, a novel angiotensin II receptor antagonist. Arch Pharm Res. 2012 Jul;35(7):1123-6. doi: 10.1007/s12272-012-0700-z.
Textbook
  • ISBN: 978-0-7020-3471-8
    Rang, H. P. and Dale, M. M. (2012). Rang and Dale's Pharmacology (7th ed.). Edinburgh: Elsevier/Churchill Livingstone.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Kanarb — Boryung Pharmaceuticals

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul